close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

New Approach to AIDS Therapy Raises Hope for Cure

A new therapeutic approach may help to remove dormant HIV infection that current treatments do not address, according to preliminary findings of a recent study published in the 13 August 2005 issue of The Lancet.

Researchers have found that valproic acid, a drug commonly used to prevent convulsions, can significantly decrease latent AIDS-virus levels within the body. "This finding, though not definitive, suggests that new approaches will allow the cure of HIV in the future," says study co-author David Margolis.

Existing therapies for HIV help to suppress the virus to very low levels. However, they do not eradicate it, as the HIV virus can sequester itself in a latent form inside immune cells. Most current anti-HIV drugs or “antiretrovirals” work to prevent these stored viruses from reactivating, but patients must take the drugs indefinitely for them to be effective. Antiretrovirals are unable to reach dormant HIV viruses.

For a person to be HIV-free – and potentially cured of AIDS – all dormant HIV viruses would have to be eradicated. The recent study is exciting because valproic acid appears to reduce levels of the dormant HIV virus, thus moving one step closer to a cure for AIDS.

Study Protocol and Results

Researchers at the University of Texas gave valproic acid to four patients already taking a combination of standard anti-HIV AIDS drugs, referred to as “highly-active antiretroviral therapy (HAART)”. The dosage of valproic acid was 500-750 mg twice daily in oral doses 16-18 weeks.

At the end of the study, researchers discovered that the number of dormant HIV cells in three patients had dropped by 75%. Also, when treatment ceased, the number of HIV cells rose to previous levels.

Comments

AIDS researcher Jean-Pierre Routy, at McGill University in Montreal, Canada, who did not participate in the study, believes it may be too early to talk about a “cure for HIV”, according to McAlary Reports. However, Routy believes the results show promise, based on their indication that valproic acid has potential to reduce levels of latent HIV virus.

"We can start to attack the virus where it is hiding," reported Routy, according to McAlary Reports. "We can hope one day that we can kill it or remove it from the body or kill the cells infected by the virus. So, yes, it’s a glimpse of hope for sure."

Other scientists cautious about the study’s results include John Siliciano, a Johns Hopkins University physician who in the 1990s helped to discover dormant HIV, reportedly told the Associated Press that, a drug has to kill virtually all cells containing latent HIV virus – not merely 75 percent of them – in order to be useful.

David Ho, an AIDS researcher at Rockefeller University in New York, believes that the finding is only a modest step forward. He noted in an NBC television interview that the test used in the study involved imprecise methods for measuring HIV, therefore the actual drop in cells containing latent HIV latent could be below 75%.

"It [the virus] is extremely difficult to get rid of, so scientists do not want to raise false hope," said Mr. Ho (McAlary Reports). "It’s a very interesting observation, but we have to be cautious to see if this observation could be confirmed."

The researchers involved in the study published in The Lancet are broadening their studies to include larger experimental groups of HIV patients, according to McAlary Reports. They believe that, if their recent findings are confirmed, the HIV virus could be attacked in stages by a variety of drugs, starting with existing combination-therapies to suppress the HIV virus, then moving on to other drugs such as valproic acid that may further reduce virus levels in the body.

Sources:
Experimental AIDS Therapy Offers Hope of Eventual Cure, David McAlary, McAlary Reports, Washington, 12 August 2005.
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. G. Lehrman et al., The Lancet, Volume 366, pages 549-555, 2005.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...